Remove Immunization Remove Packaging Remove Presentation
article thumbnail

Oncolytic viruses: past and present

European Pharmaceutical Review

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

CanSinoBIO’s inhalant has finished phase three trials in China and is presently undergoing trials in several countries. It then elicits an immune response against that spike protein. When you have mucosal immunity, the immunoglobulins called IgAs start neutralising the virus at the point of entry. The inhalant version.

Vaccines 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Container Closure Integrity Testing: A Necessity for Pharmaceutical Industry

Roots Analysis

One of the stages that require quality assurance is packaging of the drug product, as compromised packaging could have serious consequences. The defects in the packaging of container closure system could adversely affect the sterility and stability of the drug through contamination via reactive gases, humidity and microbial ingress.

article thumbnail

Prednisone for gout: Dosage, safety, and more

The Checkup by Singlecare

The kidneys typically filter out most uric acid, but uric acid crystals can accumulate in the joints if too much is present or the kidneys aren’t functioning properly. It inhibits the body’s immune system response, decreasing the inflammation and discomfort associated with gout. It might work quickly, too.

Dosage 94
article thumbnail

The next generation of immunotherapy? Innate Pharma targets NK cells

pharmaphorum

Founded in 1999, Marseille-based company Innate Pharma is on a mission to develop immunotherapies that take advantage of the body’s innate immune system. The cytokine release prompts T-cells so they can translate that first innate immune response into a long-lasting adaptive immune response.

article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

We presented our first results this year at ESMO and ESMO-IO. These new results reinforce our differentiating data package for PDC*lung01. We are very pleased to demonstrate that our innovative immunotherapy platform can induce a strong immune response in humans.

article thumbnail

Teva will appeal opioid liability ruling in New York trial

pharmaphorum

Other defendants who have opted to pay up include drugmakers AbbVie/Allergan and Endo health, which agreed $200 million and $50 million settlements, respectively, as well as medicine McKesson, Cardinal Health and AmerisourceBergen which have agreed a $1 billion package.